[
  {
    "ts": null,
    "headline": "Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial, which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss. According to the 26-week trial, semaglutide by itself resulted in […]",
    "url": "https://finnhub.io/api/news?id=7df67a18bc4ea90557b07907cd20611f70211fd6dcf527fae567c2423552820a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759438526,
      "headline": "Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management",
      "id": 136960421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial, which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss. According to the 26-week trial, semaglutide by itself resulted in […]",
      "url": "https://finnhub.io/api/news?id=7df67a18bc4ea90557b07907cd20611f70211fd6dcf527fae567c2423552820a"
    }
  },
  {
    "ts": null,
    "headline": "Does FDA Approval Expansion and Pipeline Progress Change the Bull Case for Regeneron (REGN)?",
    "summary": "In late September 2025, Regeneron Pharmaceuticals announced expanded US FDA approval of Evkeeza for very young children with homozygous familial hypercholesterolemia, and shared positive late-stage clinical trial results across its pipeline, including in rare diseases and obesity. These developments highlight Regeneron's increasing ability to diversify beyond established products and bolster its future pipeline contributions. To understand the impact of these regulatory and clinical...",
    "url": "https://finnhub.io/api/news?id=be86facd715fa625af88c5a1893d82762e23f142931466add3f05434aa511715",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759422522,
      "headline": "Does FDA Approval Expansion and Pipeline Progress Change the Bull Case for Regeneron (REGN)?",
      "id": 136960423,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In late September 2025, Regeneron Pharmaceuticals announced expanded US FDA approval of Evkeeza for very young children with homozygous familial hypercholesterolemia, and shared positive late-stage clinical trial results across its pipeline, including in rare diseases and obesity. These developments highlight Regeneron's increasing ability to diversify beyond established products and bolster its future pipeline contributions. To understand the impact of these regulatory and clinical...",
      "url": "https://finnhub.io/api/news?id=be86facd715fa625af88c5a1893d82762e23f142931466add3f05434aa511715"
    }
  },
  {
    "ts": null,
    "headline": "LEXX: Biodistribution Study Results",
    "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
    "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413840,
      "headline": "LEXX: Biodistribution Study Results",
      "id": 136959917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
      "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a"
    }
  },
  {
    "ts": null,
    "headline": "Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline",
    "summary": "Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns […]",
    "url": "https://finnhub.io/api/news?id=e854b250e13e1fca24235e9e7c320cb0648c432eb7722026ed70644e8fffb835",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759412746,
      "headline": "Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline",
      "id": 136956027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns […]",
      "url": "https://finnhub.io/api/news?id=e854b250e13e1fca24235e9e7c320cb0648c432eb7722026ed70644e8fffb835"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) through the purchase of 12,000 shares of the company’s stock. According to a recent disclosure with the SEC, the firm’s investment […]",
    "url": "https://finnhub.io/api/news?id=83f64574ef7daa5fd57644a70db73e96c3c402ac23d13c5ed1844172b7acce14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759412704,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough",
      "id": 136960428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) through the purchase of 12,000 shares of the company’s stock. According to a recent disclosure with the SEC, the firm’s investment […]",
      "url": "https://finnhub.io/api/news?id=83f64574ef7daa5fd57644a70db73e96c3c402ac23d13c5ed1844172b7acce14"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of […]",
    "url": "https://finnhub.io/api/news?id=034daeb669e50e48c3521121e3ca73338c3b58e105af49618dfb11d6dcdeff56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759363807,
      "headline": "Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials",
      "id": 136952488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of […]",
      "url": "https://finnhub.io/api/news?id=034daeb669e50e48c3521121e3ca73338c3b58e105af49618dfb11d6dcdeff56"
    }
  }
]